One-time gene-editing treatment lowered cholesterol in an early trial

An early-stage 2024 trial used a one-time CRISPR-based treatment targeting the ANGPTL3 gene in 15 people and reported LDL reductions of about 49% and triglyceride drops of about 55% in the highest-dose group; short-term side effects were minor and the FDA recommends 15 years of follow-up.

An early-stage clinical trial tested a one-time gene-editing therapy to lower dangerously high blood lipids in people with inherited or severe cholesterol problems. The study treated 15 participants in 2024 and focused on turning off the liver gene ANGPTL3. Several participants showed large reductions in LDL cholesterol and triglycerides after treatment. Short-term side effects reported in the trial were minor and resolved. Key details: - The trial enrolled 15 people and was funded by CRISPR Therapeutics. - In the highest-dose group, LDL cholesterol fell about 49% and triglycerides fell about 55% as reported in The New England Journal of Medicine. - Reported short-term side effects included back pain, nausea and elevated liver enzymes; these effects subsided. - Regulators recommended long-term monitoring; researchers report larger and longer trials are already underway and some teams are testing alternative editing approaches such as base editing. Summary: The study produced substantial short-term reductions in blood lipids for some participants, but it involved a small number of people and longer-term safety remains to be established. Researchers and regulators plan extended follow-up and larger trials to evaluate durability and any unforeseen effects, and those studies will inform whether this approach can be used more broadly.